Monitor for Nasdaq and regulatory approvals, which are conditions to close. If completed, Scilex will effectively control a newly public biotech entity, potentially re-rating its own valuation. Watch for any material adverse changes or deal termination risks.
Price Chart
Executive Summary
Scilex's indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in exchange for 100 million newly-issued Phoenix shares valued at $1 billion, after which ACEA Thera will own ~82% of the renamed combined company. This reverse merger effectively monetizes Scilex's stake in ACEA Pharma at a substantial valuation relative to Scilex's current market cap.
Key Financial Metrics
Key Facts
- Deal value agreed at $1,000,000,000 for 100,000,000 Phoenix shares at $10.00 each.
- Upon closing, ACEA Thera (Scilex subsidiary) will own approximately 82% of the combined entity.
- Phoenix Asia Holdings (PHOE) will be renamed ACEA Pharma, Inc. and continue trading on Nasdaq.
- Closing expected in Q2 2026 subject to regulatory, Nasdaq, and customary conditions.
Financial Impact
The $1 billion deal valuation represents a massive multiple of Scilex's <$2M warrant market cap, potentially unlocking significant value for Scilex shareholders.
Risk Factors
- Deal may fail to close due to regulatory or stock exchange issues.
- No financials of ACEA Pharma disclosed; valuation may not be realized.
- Scilex warrants (SCLXW) may see price volatility based on deal progress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205839 |
| Document: sclx-ex99_1.htm | 0001193125-26-205839 |
| Document: 0001193125-26-205839-index-headers.html | 0001193125-26-205839 |
| Document: 0001193125-26-205839-index.html | 0001193125-26-205839 |
| Document: 0001193125-26-205839.txt | 0001193125-26-205839 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 17w ago | S-3 | $0.1360 $0.1800 | ▼ −32.35% | ▼ −33.35% | — |
May 26, 2026 18w ago | EFFECT | $0.1360 $0.1360 | · 0.00% | ▼ −2.06% | — |
May 5, 2026 21w ago | 8-K | $0.1360 $0.1360 | · 0.00% | ▼ −4.95% | — |
Apr 28, 2026 22w ago | 8-K | $0.1360 $0.1360 | · 0.00% | ▼ −6.05% | — |
Apr 16, 2026 24w ago | S-3 | $0.1360 $0.1360 | · 0.00% | ▼ −5.37% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access